GeneDx Hldgs Q1 2024 Adj EPS $(0.33) Beats $(0.67) Estimate, Sales $62.422M Beat $49.463M Estimate
Portfolio Pulse from Benzinga Newsdesk
GeneDx Hldgs (NASDAQ:WGS) reported Q1 2024 adjusted EPS of $(0.33), surpassing the $(0.67) estimate, with sales of $62.422M exceeding the $49.463M forecast, marking a 44.70% increase from the previous year.

April 29, 2024 | 8:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GeneDx Hldgs reported a significant beat on both EPS and sales estimates for Q1 2024, with a notable year-over-year sales increase.
Beating both EPS and sales estimates significantly, especially by such large margins, is likely to instill investor confidence and could lead to a positive short-term price movement for WGS. The substantial year-over-year sales growth further underscores the company's strong performance and potential for future growth, making this news highly relevant and important for investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100